Skip to main content
. 2024 Nov 5;18:313–326. doi: 10.2147/BTT.S489363

Figure 5.

Figure 5

Overall Survival curve of the 56 patients with previously treated advanced non-small cell lung cancer who received anlotinib plus PD-1 inhibitors.